A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor

Pancreatic Ductal Adenocarcinoma (PDAC) is a disease with a great heterogeneity in the response to treatments. To improve the responsiveness to treatments there are two different approaches, the first one consist to develop new and more efficient drugs that intent to cure all patients and the second...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncotarget
Κύριοι συγγραφείς: Gayet, Odile, Loncle, Celine, Duconseil, Pauline, Gilabert, Marine, Lopez, Maria Belen, Moutardier, Vincent, Turrini, Olivier, Calvo, Ezequiel, Ewald, Jacques, Giovannini, Marc, Gasmi, Mohamed, Bories, Erwan, Barthet, Marc, Ouaissi, Mehdi, Goncalves, Anthony, Poizat, Flora, Raoul, Jean Luc, Secq, Veronique, Garcia, Stephane, Viens, Patrice, Dusetti, Nelson, Iovanna, Juan
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Impact Journals LLC 2014
Θέματα:
Research Paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4359252/
https://ncbi.nlm.nih.gov/pubmed/25481873
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια